drugset / Trial / NCT03877055
A Study of Copanlisib and Ibrutinib in Mantle Cell Lymphoma
NaSequentialOpen-labelTreatment
Summary
The purpose of this study is to test the safety and any good and bad side effects of combining 2 study drugs, copanlisib and ibrutinib. This combination of drugs could shrink your Mantle Cell Lymphoma (MCL), but it could also cause side effects. Both these drugs have been given to people before, but this is the first time that they are being given together.
Timeline
- Start
- 2019-03-13
- Primary completion
- 2022-10-07
- Completion
- 2022-10-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Copanlisib | Small molecule | — | Intravenous |
| Subject | Ibrutinib | Small molecule | — | Oral |